Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H13ClN2O2.ClH |
| Molecular Weight | 337.201 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=CC=CC=C3
InChI
InChIKey=GPVUAFAZVYNKRQ-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O2.ClH/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10;/h2-9,15,20H,1H3;1H
DescriptionSources: http://www.drugbank.ca/drugs/DB00231Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018163s054lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00231
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018163s054lbl.pdf
Temazepam is a benzodiazepine used as a hypnotic agent in the management of insomnia. Temazepam produces CNS depression at limbic, thalamic, and hypothalamic levels of the CNS. Temazepam increases the affinity of the neurotransmitter gamma-aminobutyric acid (GABA) for GABA receptors by binding to benzodiazepine receptors. Results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action. Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Temazepam is used for the short-term treatment of insomnia (generally 7-10 days).
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
865 ng/mL |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
964 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1560 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2574013 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1800 ng × h/mL |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.8 h |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2574013 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4% |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
26 mg single, intravenous Dose: 26 mg Route: intravenous Route: single Dose: 26 mg Sources: |
healthy, 18 - 24 years Health Status: healthy Age Group: 18 - 24 years Sex: M+F Sources: |
|
40 mg single, oral |
unhealthy, 42 years (range: 22 - 59 years) n = 14 Health Status: unhealthy Age Group: 42 years (range: 22 - 59 years) Sex: M+F Population Size: 14 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Citalopram and sexual side effects of selective serotonin reuptake inhibitors. | 1999 May |
|
| High-speed liquid chromatography/tandem mass spectrometry using a monolithic column for high-throughput bioanalysis. | 2001 |
|
| Behaviour therapy for chronic insomnia. | 2001 Feb |
|
| Digitally assisted acromioplasty: the effect of interscalene block on this new surgical technique. | 2001 Jan |
|
| Culture of porcine hepatocytes: the dogma of exogenous matrix revisited. | 2001 Jul |
|
| Comparison of monomeric and polymeric amino acid based surfactants for chiral separations. | 2001 Jul 13 |
|
| Urinary excretion of diazepam metabolites in healthy volunteers and drug users. | 2001 May |
|
| Drug related deaths in the Strathclyde region of Scotland, 1995-1998. | 2001 Oct 15 |
|
| Determination of partial solubility parameters of five benzodiazepines in individual solvents. | 2001 Oct 9 |
|
| The simultaneous determination of diazepam and its three metabolites in dog plasma by high-performance liquid chromatography with mass spectroscopy detection. | 2001 Sep |
|
| Digit loss following misuse of temazepam. | 2002 Apr 15 |
|
| Recent trends in benzodiazepine use by injecting drug users in Victoria and Tasmania. | 2002 Dec |
|
| Long-term effects of and physiological responses to nitrous oxide gas treatment during alcohol withdrawal: a double-blind, placebo-controlled trial. | 2002 Dec |
|
| Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. | 2002 Dec 5 |
|
| Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? | 2002 Jul |
|
| Bio-compatible in-tube solid-phase microextraction capillary for the direct extraction and high-performance liquid chromatographic determination of drugs in human serum. | 2002 Jul 19 |
|
| [Adverse renal effects of legal and illicit drugs]. | 2002 Mar |
|
| Acute performance-impairing and subject-rated effects of triazolam and temazepam, alone and in combination with ethanol, in humans. | 2002 Mar |
|
| Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation. | 2002 Mar |
|
| [Fatal outcome of poisoning with the benzodiazepines flunitrazepam and diazepam]. | 2002 Mar-Apr |
|
| Melatonin and zopiclone: the relationship between sleep propensity and body temperature. | 2002 May 1 |
|
| Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions. | 2002 May 8 |
|
| Insomnia. Diagnosis and management. | 2002 Nov |
|
| Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. | 2003 Dec |
|
| Association of benzodiazepine injection with the prescription of temazepam capsules. | 2003 Jun |
|
| Effects of diazepam and its metabolites on nocturnal melatonin secretion in the rat pineal and Harderian glands. A comparative in vivo and in vitro study. | 2003 Mar |
|
| Interaction of alcohol and drugs in fatal poisonings. | 2003 May |
|
| Fast analysis using monolithic columns coupled with high-flow on-line extraction and electrospray mass spectrometric detection for the direct and simultaneous quantitation of multiple components in plasma. | 2003 May 25 |
|
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | 2003 Nov 17 |
|
| [Benzodiazepines and forensic aspects]. | 2003 Nov-Dec |
|
| Pharmacokinetics and drug interactions of the sedative hypnotics. | 2003 Winter |
|
| Residual effects of hypnotics: epidemiology and clinical implications. | 2004 |
|
| Changes in fatalities due to overdose of anxiolytic and sedative drugs in the UK (1983-1999). | 2004 |
|
| Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2004 Aug |
|
| Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. | 2004 Feb |
|
| CNS effects of sumatriptan and rizatriptan. | 2004 Jan |
|
| Monitoring of drugs and metabolites in whole blood by restricted-access solid-phase microextraction coupled to liquid chromatography-mass spectrometry. | 2004 Jan 30 |
|
| Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. | 2004 Jul |
|
| Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. | 2004 Jun |
|
| An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. | 2004 Mar 24 |
|
| [Diphenhydramin-overdose: anticholinergic symptoms, EEG-findings in the course and drug treatment of a gerontopsychiatric patient]. | 2004 Nov |
|
| 'Hypnotic' prescription patterns in a large managed-care population. | 2004 Sep |
|
| Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. | 2005 Mar |
Patents
Sample Use Guides
While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency. In elderly or debilitated patients, it is recommended that therapy be initiated with 7.5 mg until individual responses are determined.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
97598-16-8
Created by
admin on Sat Dec 16 01:47:12 GMT 2023 , Edited by admin on Sat Dec 16 01:47:12 GMT 2023
|
PRIMARY | |||
|
DBSALT002272
Created by
admin on Sat Dec 16 01:47:12 GMT 2023 , Edited by admin on Sat Dec 16 01:47:12 GMT 2023
|
PRIMARY | |||
|
70376607
Created by
admin on Sat Dec 16 01:47:12 GMT 2023 , Edited by admin on Sat Dec 16 01:47:12 GMT 2023
|
PRIMARY | |||
|
IA4EP07006
Created by
admin on Sat Dec 16 01:47:12 GMT 2023 , Edited by admin on Sat Dec 16 01:47:12 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
